Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil

References

• American Urological Association (AUA). [AUA] Guideline: The Management of Erectile Dysfunction, 2005. Updated 2007; reviewed and validity confirmed 2011. Available at: http://www.auanet.org/education/guidelines/erectile-dysfunction.cfm [Last accessed July 2013]
   Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, et al. for the European Association of Urology (EAU). Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14
   PubMed Web of Science ®Google Scholar
• Viagra [package insert]. New York, NY, USA: Pfizer Inc., 2014
   Google Scholar
• Cialis [package insert]. Indianapolis, IN, USA: Eli Lilly and Company, 2014
   Google Scholar
• Levitra [package insert]. Whippany, NJ, USA: Bayer HealthCare Pharmaceuticals Inc., 2014
   Google Scholar
• Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results from a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9
   PubMed Web of Science ®Google Scholar
• Rajfer J, Aliotta PJ, Steidle CP, et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007;19:95-103
   PubMed Web of Science ®Google Scholar
• Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25:138-46
   PubMed Web of Science ®Google Scholar
• Wagner G, Montorsi F, Auerbach S, et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001;56:M113-19
   PubMed Web of Science ®Google Scholar
• Fujisawa M, Sawada K. Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. Arch Androl 2004;50:255-60
   PubMed Web of Science ®Google Scholar
• Skoumal R, Chen J, Kula K, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:362-9
   PubMed Web of Science ®Google Scholar
• Carrier S, Brock GB, Pommerville PJ, et al. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005;2:685-98
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Montorsi F, Giuliano F, et al. for the North American and European Vardenafil Study Group. Vardenafil restores erectile function to normal range in men with erectile dysfunction. J Sex Med 2007;4:152-61
   PubMed Web of Science ®Google Scholar
• Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14:S99-104
   PubMed Web of Science ®Google Scholar
• McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300
   PubMed Web of Science ®Google Scholar
• Swindle RW, Cameron AE, Lockhart DC, et al. The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004;33:19-30
   PubMed Web of Science ®Google Scholar
• Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19:119-23
   PubMed Web of Science ®Google Scholar
• Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-5
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Burnett AL, Eardley I, et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU Int 2005;96:857-63
   PubMed Web of Science ®Google Scholar
• Young JM, Feldman RA, Auerbach SM, et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005;26:310-18
   PubMed Web of Science ®Google Scholar
• Eardley I, Mirone V, Montorsi F, et al. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32
   PubMed Web of Science ®Google Scholar
• Hatzichristou D, Haro JM, Martin-Morales A, et al.; for the EDOS Group. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007;61:1850-62
   PubMed Web of Science ®Google Scholar
• Rubio-Aurioles E, Reyes LA, Borregales L, et al. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. Curr Med Res Opin 2013;29:695-706
   PubMed Web of Science ®Google Scholar
• Dean J, Hackett GI, Gentile V, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61
   PubMed Web of Science ®Google Scholar
• Eardley I, Montorsi F, Jackson G, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicenter, randomized, open-label, crossover study. BJU Int 2007;100:122-9
   PubMed Web of Science ®Google Scholar
• Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012;9:1418-29
   PubMed Web of Science ®Google Scholar
• McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25
   PubMed Web of Science ®Google Scholar
• Buvat J, Büttner H, Hatzimouratidis K, et al. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013;10:1592-602
   PubMed Web of Science ®Google Scholar
• Kim ED, Seftel AD, Goldfischer ER, et al. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2014;11:820-30
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30
   PubMed Web of Science ®Google Scholar
• Schulman CC, Shen W, Stothard DR, et al. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004;64:783-8
   PubMed Web of Science ®Google Scholar
• Araujo AB, Allen KR, Ni X, et al. Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. J Sex Med 2012;9:169-79
   PubMed Web of Science ®Google Scholar